Quantitative measurement of [Na+] and [K+] in postmortem human brain tissue indicates disturbances in subjects with Alzheimer's disease and dementia with Lewy bodies

Journal of Alzheimer's Disease

Volumn 44, Issue 3, 2015, Pages 851-857

  Graham, Stewart F ^a,d   Nasarauddin, Muhammad Bin ^a   Carey, Manus ^a   McGuinness, Bernadette ^a   Holscher, Christian ^b   Kehoe, Patrick G ^c   Love, Seth ^c   Passmore, Anthony P ^a   Elliott, Christopher T ^a   Meharg, Andrew ^a   Green, Brian D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d Beaumont Research Institute   (United States)

Author keywords

Alzheimer's disease; dementia with Lewy bodies; human brain; ICP MS; potassium; sodium

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; POTASSIUM ION; SODIUM ION; TAU PROTEIN; POTASSIUM; SODIUM;

ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CADAVER; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FRONTAL LOBE; GENOTYPE; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; PARIETAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TISSUE LEVEL; AGED; AMYLOID PLAQUE; AUTOPSY; BRAIN; BRAIN CHEMISTRY; CASE CONTROL STUDY; FEMALE; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AUTOPSY; BRAIN; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POTASSIUM; SEVERITY OF ILLNESS INDEX; SODIUM; STATISTICS, NONPARAMETRIC; TANDEM MASS SPECTROMETRY;

EID: 84922643551     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141869     Document Type: Article

References (20)

1. Monge-Argiles JA, Munoz-Ruiz C, Pampliega-Perez A, Gomez-Lopez MJ, Sanchez-Paya J, Rodriguez Borja E, Ruiz-Vegara M, Montoya-Gutierrez FJ, Leiva-Santana C (2011) Biomarkers of Alzheimer's disease in the cerebrospinal fluid of Spanish patients with mild cognitive impairment. Neurochem Res 36, 986-993.
2. Holscher C (2005) Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev Neurosci 16, 181-212.
3. Kehoe PG, Miners S, Love S (2009) Angiotensins in Alzheimer's disease-friend or foe? Trends Neurosci 32, 619-628.
4. Vitvitsky VM, Garg SK, Keep RF, Albin RL, Banerjee R (2012) Na+ and K+ ion imbalances in Alzheimer's disease. Biochim Biophys Acta 1822, 1671-1681.
5. Hattori N, Kitagawa K, Higashida T, Yagyu K, Shimohama S, Wataya T, Perry G, Smith MA, Inagaki C (1998) CI-ATPase and Na+/K(+)-ATPase activities in Alzheimer's disease brains. Neurosci Lett 254, 141-144.
6. Colvin RA, Bennett JW, Colvin SL, Allen RA, Martinez J, Miner GD (1991) Na+/Ca2+exchange activity is increased in Alzheimer's disease brain tissues. Brain Res 543, 139-147.
7. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of Abeta1-42. J Neurochem 78, 413-416.
8. Graham SF, Nasaruddin MB, CareyM, Holscher C, McGuinness B, Kehoe PG, Love S, Passmore P, Elliott CT, Meharg AA, Green BD (2014) Age-associated changes of brain copper, iron, and zinc in Alzheimer's disease and dementia with Lewy bodies. J Alzheimers Dis 42, 1407-1413.
9. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, DicksonDW, Duyckaerts C, FroschMP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on Aging, Alzheimer's, Association (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
10. McKeith IG, DicksonDW,Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872.
11. Chalmers K, Wilcock GK, Love S (2003) APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 29, 231-238.
12. Ballard CG, Chalmers KA, Todd C, McKeith IG, O'Brien JT, Wilcock G, Love S, PerryEK(2007) Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 68, 1726-1729.
13. Chalmers KA, Wilcock GK, Vinters HV, Perry EK, Perry R, Ballard CG, Love S (2009) Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol 256, 717-720.
14. Attwell D, LaughlinSB(2001)Anenergy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21, 1133-1145.
15. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study, Group (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344, 1343-1350.
16. Khatri N, Man H (2013) Synaptic activity and bioenergy homeostasis: Implications in brain trauma and neurodegenerative diseases. Front Neurol 4, 1-11.
17. Etcheberrigaray R, Ito E, Oka K, Tofel-Grehl B, Gibson GE, Alkon DL (1993) Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease. Proc Natl Acad Sci U S A 90, 8209-8213.
18. Etcheberrigaray R, Ito E, Kim CS, Alkon DL (1994) Soluble beta-amyloid induction of Alzheimer's phenotype for human fibroblast K+ channels. Science 264, 276-279.
19. Plant LD, Boyle JP, Thomas NM, Hipkins NJ, Benedikz E, Hooper NM, Henderson Z, Vaughan PF, Peers C, Cowburn RF, Pearson HA (2002) Presenilin-1 mutations alter K+ currents in the human neuroblastoma cell line, SH-SY5Y. Neuroreport 13, 1553-1556.
20. Shieh CC, Coghlan M, Sullivan JP, GopalakrishnanM(2000) Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52, 557-594.